News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,263 Results
Type
Article (14253)
Company Profile (281)
Press Release (253729)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79548)
Career Advice (152)
Deals (13245)
Drug Delivery (35)
Drug Development (50489)
Employer Resources (31)
FDA (5727)
Job Trends (5133)
News (144494)
Policy (10033)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21678)
ALS (64)
Alzheimer's disease (848)
Antibody-drug conjugate (ADC) (100)
Approvals (5755)
Artificial intelligence (124)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (58)
Brain cancer (20)
Breast cancer (155)
Cancer (1479)
Cardiovascular disease (116)
Career advice (133)
Career pathing (2)
CAR-T (118)
Cell therapy (334)
Cervical cancer (8)
Clinical research (41106)
Collaboration (542)
Compensation (258)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (164)
Cystic fibrosis (76)
Data (1524)
Denatured (11)
Depression (30)
Diabetes (139)
Diagnostics (1300)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29855)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48666)
Executive appointments (464)
FDA (6425)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (254)
GLP-1 (366)
Government (1080)
Grass and pollen (2)
Guidances (22)
Healthcare (6596)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (93)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (114)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7288)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (209)
Leadership (3)
Legal (1386)
Liver cancer (33)
Lung cancer (205)
Lymphoma (101)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (53)
Medical device (2599)
Medtech (2600)
Mergers & acquisitions (6288)
Metabolic disorders (390)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1257)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (43)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (130)
Patient recruitment (78)
Peanut (35)
People (25651)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14529)
Phase II (19114)
Phase III (12083)
Pipeline (810)
Policy (45)
Postmarket research (852)
Preclinical (6151)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8642)
Reports (15)
Research institute (939)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (60)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1976)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (213)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (97)
Last 7 days (520)
Last 30 days (1519)
Last 365 days (19576)
2025 (6299)
2024 (20575)
2023 (22464)
2022 (26860)
2021 (27819)
2020 (23364)
2019 (16224)
2018 (11738)
2017 (13749)
2016 (11839)
2015 (14350)
2014 (10393)
2013 (7484)
2012 (7533)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17319)
Australia (2935)
California (3865)
Canada (1141)
China (360)
Colorado (149)
Connecticut (152)
Delaware (102)
Europe (37294)
Florida (466)
Georgia (116)
Idaho (16)
Illinois (232)
India (10)
Indiana (91)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (473)
Massachusetts (3083)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (968)
New Mexico (12)
New York (1059)
North Carolina (554)
North Dakota (5)
Northern California (1702)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (741)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1489)
Tennessee (25)
Texas (449)
United States (13290)
Utah (53)
Virginia (79)
Washington D.C. (30)
Washington State (352)
Wisconsin (15)
268,263 Results for "gammadelta therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences
April 30, 2025
·
6 min read
Press Releases
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
April 29, 2025
·
7 min read
Press Releases
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
April 1, 2025
·
2 min read
Press Releases
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
March 4, 2025
·
8 min read
Drug Development
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones.
April 9, 2024
·
7 min read
Pharm Country
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
IN8bio presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy 2024 Annual Meeting.
May 13, 2024
·
5 min read
Drug Development
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell platform, INB-300.
March 5, 2024
·
5 min read
Press Releases
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
December 10, 2024
·
8 min read
Pharm Country
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
LAVATherapeutics N.V. (Nasdaq:LVTX), a company in the clinical stage of immuno-oncology, is dedicated to advancing its unique Gammabody™ platform, which involves the development of bispecific gamma-delta T cell engagers.
June 1, 2023
·
5 min read
Pharm Country
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2)
May 6, 2024
·
1 min read
1 of 26,827
Next
